Loading data for REPL — first visit, this takes a few seconds.

Replimune Group, Inc. (REPL)

NasdaqGS: REPL · 即時價格 · USD

15.50

-0.10 (-0.64%)

收盤價： Sep 04, 2026, 8:00 PM

15.10

+0.38%

盤後: 7:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	15.44
市值	1.42B
營收 (ttm)	n/a
淨利（ttm）	-297M
	0.94
	-3.15
	n/a
	-7.38
P/B (ttm)	11.96
P/S (ttm)	0.00
財報日期	Nov 5, 2026

賣價	19.84
成交量	2,386,210
20 日平均成交量	5,021,819
開盤價	15.40
前收盤價	15.60
當日區間	15.40 - 15.87
52 週範圍	1.50 - 16.15
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 REPL

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) a...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jul 20, 2018

員工 465

證券交易所 NasdaqGS

股票代號 REPL

網站 https://www.replimune.com

完整的公司簡介

財務表現

Replimune 在 2026 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -313.94M，較前期增加 26.95%。

財務報表

財報驚奇

Replimune 已於 Aug 14, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.72 超出預期 0.05, 年增 24.21% 成長.

下次財報發布

Replimune Group, Inc. 的下次財報預計於 Nov 5, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

1 週前 · Stocktwits

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

3 週前 · Simply Wall St.

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

Replimune Group (NasdaqGS:REPL) received FDA accelerated approval for TUDRIQEV (RP1) in combination with nivolumab to treat advanced cutaneous melanoma after anti PD 1 therapy. This marks the first FD...